AR075422A1 - Composicion farmaceutica que comprende linagliptina, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma - Google Patents
Composicion farmaceutica que comprende linagliptina, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la mismaInfo
- Publication number
- AR075422A1 AR075422A1 ARP100100419A ARP100100419A AR075422A1 AR 075422 A1 AR075422 A1 AR 075422A1 AR P100100419 A ARP100100419 A AR P100100419A AR P100100419 A ARP100100419 A AR P100100419A AR 075422 A1 AR075422 A1 AR 075422A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical
- prevent
- reduce
- pharmaceutical composition
- treat
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 3
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical group N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 230000037396 body weight Effects 0.000 abstract 3
- 239000008103 glucose Substances 0.000 abstract 3
- 229960002397 linagliptin Drugs 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 239000003826 tablet Substances 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 206010054805 Macroangiopathy Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 150000001555 benzenes Chemical group 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 238000009826 distribution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000007941 film coated tablet Substances 0.000 abstract 1
- 125000005640 glucopyranosyl group Chemical group 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas de linagliptina, formas farmacéuticas, su preparacion, su uso y métodos para tratar trastornos metabolicos. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende linagliptina como un primer ingrediente farmacéutico activo y uno o más excipientes. Reivindicacion 3: La composicion farmacéutica segun la reivindicacion 1, caracterizada porque el primer ingrediente activo tiene una distribucion de tamano de partícula de X90 < 200 mm. Reivindicacion 8: La composicion farmacéutica segun una o más de las reivindicaciones precedentes, caracterizada porque comprende: 0,5 - 25% de los uno o dos ingredientes activos; 40 - 88% de los uno o más diluyentes; 0,5 - 20% de los uno o más aglutinantes; y 0,5 - 20% de los uno o más disgregantes; donde los porcentajes están en peso de la composicion total. Reivindicacion 9: La composicion farmacéutica segun una o más de las reivindicaciones 1 a 8, caracterizada porque está en la forma de un granulado, una cápsula, un comprimido o un comprimido recubierto con película. Reivindicacion 11: La forma farmacéutica segun la reivindicacion 10, caracterizada porque es una forma farmacéutica solida, en particular una cápsula o un comprimido. Reivindicacion 12: La forma farmacéutica segun la reivindicacion 10 u 11, caracterizada porque comprende linagliptina como primer ingrediente farmacéutico activo en una cantidad de 0,1 a 30 mg. Reivindicacion 13: La forma farmacéutica segun la reivindicacion 10, 11 o 12, caracterizada porque comprende adicionalmente un derivado bencénico sustituido con glucopiranosilo de la formula (1) como se define en la reivindicacion 2, como segundo ingrediente farmacéutico activo en una cantidad de 0,5 a 100 mg. Reivindicacion 22: Uso de una composicion farmacéutica segun una de las reivindicaciones 1 a 9 caracterizado porque es para la fabricacion de un medicamento para: prevenir, reducir la progresion, retrasar o tratar un trastorno metabolico seleccionado del grupo que consiste en diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteracion de la tolerancia a la glucosa, alteracion de la glucosa sanguínea en ayunas, hiperglucemia, hiperglucemia posprandial, sobrepeso, obesidad y síndrome metabolico; o mejorar el control glucémico y/o reducir la glucosa plasmática en ayunas, la glucosa plasmática posprandial y/o la hemoglobina glicosilada HbA1c; o prevenir, reducir, retrasar o invertir la progresion desde la alteracion de la tolerancia a la glucosa, la resistencia a la insulina y/o el síndrome metabolico hasta la diabetes mellitus de tipo 2; o prevenir, reducir la progresion, retrasar o tratar una afeccion o trastorno seleccionado del grupo de complicaciones de la diabetes mellitus, tales como cataratas y enfermedades micro- y macrovasculares, tales como nefropatía, retinopatía, neuropatía, isquemia tisular, arterioesclerosis, infarto de miocardio, ictus y enfermedad oclusiva de las arterias periféricas; o reducir el peso corporal o prevenir un aumento del peso corporal o facilitar una reduccion del peso corporal; o prevenir, reducir, retrasar o tratar la degeneracion de las células beta pancreáticas y/o el declive de la funcionalidad de las células beta pancreáticas, y/o mejorar y/o restablecer la funcionalidad de las células beta pancreáticas y/o restablecer la funcionalidad de la secrecion de insulina pancreática; o prevenir, reducir, retrasar o tratar enfermedades o trastornos atribuidos a una acumulacion anormal de grasa en el hígado; o mantener y/o mejorar la sensibilidad a la insulina y/o tratar o prevenir la hiperinsulinemia y/o la resistencia a la insulina; en un paciente que lo necesite.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15230609P | 2009-02-13 | 2009-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075422A1 true AR075422A1 (es) | 2011-03-30 |
Family
ID=42115453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100419A AR075422A1 (es) | 2009-02-13 | 2010-02-12 | Composicion farmaceutica que comprende linagliptina, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20100209506A1 (es) |
| EP (2) | EP2395984B1 (es) |
| JP (1) | JP5456795B2 (es) |
| KR (2) | KR101894228B1 (es) |
| CN (3) | CN102316861A (es) |
| AP (1) | AP2810A (es) |
| AR (1) | AR075422A1 (es) |
| AU (1) | AU2010212866B2 (es) |
| BR (1) | BRPI1008556A2 (es) |
| CA (1) | CA2752434C (es) |
| CL (1) | CL2011001758A1 (es) |
| CO (1) | CO6410287A2 (es) |
| DK (1) | DK2395984T3 (es) |
| EA (1) | EA023243B1 (es) |
| EC (1) | ECSP11011276A (es) |
| ES (1) | ES2606050T3 (es) |
| GE (1) | GEP20135963B (es) |
| HU (1) | HUE031088T2 (es) |
| IL (1) | IL213721A0 (es) |
| MA (1) | MA33045B1 (es) |
| MX (1) | MX338712B (es) |
| MY (1) | MY159630A (es) |
| NZ (1) | NZ594022A (es) |
| PE (1) | PE20120018A1 (es) |
| PL (1) | PL2395984T3 (es) |
| SG (1) | SG173036A1 (es) |
| TN (1) | TN2011000414A1 (es) |
| TW (1) | TWI483943B (es) |
| UA (1) | UA103915C2 (es) |
| UY (1) | UY32427A (es) |
| WO (1) | WO2010092124A1 (es) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| MX2008002457A (es) * | 2005-09-08 | 2008-04-07 | Boehringer Ingelheim Int | Formas cristalinas de 1-cloro-4-(??-d-clucopiranos-1-il). |
| PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| JP2010507629A (ja) * | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| NZ590788A (en) | 2008-09-08 | 2012-11-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| SI2395983T1 (sl) | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
| CN105147662A (zh) * | 2009-02-13 | 2015-12-16 | 贝林格尔·英格海姆国际有限公司 | 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物及其药物剂型、制备方法与用途 |
| JP2012517977A (ja) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| AP2011005819A0 (en) | 2009-03-31 | 2011-08-31 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators. |
| ES2546762T3 (es) | 2009-09-30 | 2015-09-28 | Boehringer Ingelheim International Gmbh | Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo |
| JP5736377B2 (ja) * | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法 |
| US10610489B2 (en) * | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| CA2782179C (en) | 2009-11-27 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| SG10201501535UA (en) * | 2010-03-03 | 2015-04-29 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| JP5843855B2 (ja) | 2010-06-24 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病療法 |
| EP2603511B1 (en) | 2010-08-12 | 2017-03-15 | Boehringer Ingelheim International GmbH | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| ES2777890T3 (es) * | 2010-11-15 | 2020-08-06 | Boehringer Ingelheim Int | Terapia antidiabética vasoprotectora y cardioprotectora |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
| BR112014020372A8 (pt) | 2012-02-16 | 2018-01-23 | Teva Pharma | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102627535A (zh) * | 2012-03-31 | 2012-08-08 | 天津药物研究院 | 含1,1-二苯基环丙基结构的化合物的制备方法 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| EP2849754B1 (en) * | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| EP2854812A1 (en) * | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014009970A2 (en) * | 2012-07-09 | 2014-01-16 | Hetero Research Foundation | Linagliptin solid dispersion |
| US9381199B2 (en) | 2012-07-09 | 2016-07-05 | Hetero Research Foundation | Linagliptin solid dispersion |
| EP3311803A1 (en) * | 2012-08-13 | 2018-04-25 | Sandoz AG | Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
| EP2908806A1 (en) * | 2012-10-09 | 2015-08-26 | Boehringer Ingelheim International GmbH | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets |
| WO2014074381A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| WO2014080384A1 (en) | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Pharmaceutical composition of linagliptin |
| US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| EA033286B1 (ru) | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
| TR201310724A2 (tr) * | 2013-09-12 | 2015-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Linagliptinin farmasotik formulasyonları. |
| WO2015038854A1 (en) * | 2013-09-13 | 2015-03-19 | R.P. Scherer Technologies, Llc | Encased-pellet tablets |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2016104643A1 (ja) * | 2014-12-25 | 2016-06-30 | 田辺三菱製薬株式会社 | 糖尿病治療用固形製剤 |
| CN104623684B (zh) * | 2015-02-11 | 2020-12-25 | 浙江华海药业股份有限公司 | 一种恩格列净甘露醇组合物的制备方法 |
| KR102259146B1 (ko) | 2015-03-05 | 2021-06-01 | 동우 화인켐 주식회사 | 인듐 산화막의 식각액 조성물 및 이를 이용한 표시 기판의 제조 방법 |
| EP3091076A1 (en) | 2015-05-07 | 2016-11-09 | Limagrain Europe | Polynucleotide responsible of haploid induction in maize plants and related processes |
| WO2017060861A2 (en) * | 2015-10-07 | 2017-04-13 | Steerlife India Private Limited | Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content |
| US20180344647A1 (en) * | 2015-12-04 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN107174571B (zh) * | 2016-03-09 | 2021-01-08 | 四川科伦药物研究院有限公司 | 一种利格列汀及其盐、酯、衍生物的药物组合物及其制备方法 |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| WO2018087132A1 (en) | 2016-11-10 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
| TR201720515A2 (tr) * | 2017-12-15 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu |
| KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
| CN111110949B (zh) * | 2018-11-01 | 2021-07-09 | 上海市第六人民医院 | 胰岛素注射量确定方法及装置、计算机存储介质及设备 |
| US11202766B1 (en) * | 2019-04-23 | 2021-12-21 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including hydrocodone bitartrate and guaifenesin |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969349B1 (en) | 1997-09-17 | 2005-11-29 | Origin Medsystem, Inc. | Device to permit offpump beating heart coronary bypass surgery |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
| UA84275C2 (ru) * | 2002-08-21 | 2008-10-10 | Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг | 8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение как лекарственных средств |
| US7674486B2 (en) * | 2003-05-14 | 2010-03-09 | Indus Biotech Pvt. Ltd. | Synergistic composition for the treatment of diabetes mellitus |
| PT3366283T (pt) | 2004-01-20 | 2021-12-02 | Novartis Ag | Formulação e processo de compressão direta |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CN103030617A (zh) | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| ATE407938T1 (de) | 2004-12-16 | 2008-09-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| CN101106977A (zh) * | 2005-01-18 | 2008-01-16 | 诺瓦提斯公司 | 直接压片的配方及方法 |
| ES2338041T3 (es) | 2005-04-15 | 2010-05-03 | Boehringer Ingelheim International Gmbh | Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt. |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| EP1924571B1 (en) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| MX2008002457A (es) | 2005-09-08 | 2008-04-07 | Boehringer Ingelheim Int | Formas cristalinas de 1-cloro-4-(??-d-clucopiranos-1-il). |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| SG166115A1 (en) * | 2005-09-30 | 2010-11-29 | Boehringer Ingelheim Vetmed | Pharmaceutical preparation containing meloxicam |
| JP2009531291A (ja) | 2006-02-15 | 2009-09-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| JP2010507629A (ja) * | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| TW200829258A (en) * | 2006-11-06 | 2008-07-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| CA3007700A1 (en) * | 2006-11-09 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| WO2008062273A2 (en) * | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| PE20090603A1 (es) * | 2007-08-16 | 2009-06-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv |
| CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20090279199A1 (en) | 2008-05-12 | 2009-11-12 | Samsung Electronics Co., Ltd. | Method and apparatus for reducing slider contact probability in a load-unload (LUL) hard disk drive |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
-
2010
- 2010-02-10 UY UY0001032427A patent/UY32427A/es not_active Application Discontinuation
- 2010-02-11 JP JP2011549561A patent/JP5456795B2/ja active Active
- 2010-02-11 DK DK10703474.6T patent/DK2395984T3/en active
- 2010-02-11 NZ NZ594022A patent/NZ594022A/xx unknown
- 2010-02-11 BR BRPI1008556-4A patent/BRPI1008556A2/pt not_active Application Discontinuation
- 2010-02-11 MY MYPI2011003381A patent/MY159630A/en unknown
- 2010-02-11 GE GEAP201012370A patent/GEP20135963B/en unknown
- 2010-02-11 KR KR1020177008948A patent/KR101894228B1/ko active IP Right Grant
- 2010-02-11 EP EP10703474.6A patent/EP2395984B1/en active Active
- 2010-02-11 AP AP2011005776A patent/AP2810A/xx active
- 2010-02-11 WO PCT/EP2010/051735 patent/WO2010092124A1/en active Application Filing
- 2010-02-11 MA MA34090A patent/MA33045B1/fr unknown
- 2010-02-11 US US12/704,019 patent/US20100209506A1/en not_active Abandoned
- 2010-02-11 AU AU2010212866A patent/AU2010212866B2/en active Active
- 2010-02-11 ES ES10703474.6T patent/ES2606050T3/es active Active
- 2010-02-11 CN CN2010800076636A patent/CN102316861A/zh active Pending
- 2010-02-11 EA EA201101190A patent/EA023243B1/ru active Protection Beyond IP Right Term
- 2010-02-11 MX MX2011008171A patent/MX338712B/es active IP Right Grant
- 2010-02-11 KR KR1020117018777A patent/KR20110114658A/ko not_active Application Discontinuation
- 2010-02-11 CN CN201310651594.8A patent/CN103751192A/zh active Pending
- 2010-02-11 SG SG2011051927A patent/SG173036A1/en unknown
- 2010-02-11 CN CN201310655506.1A patent/CN103751193B/zh active Active
- 2010-02-11 PL PL10703474T patent/PL2395984T3/pl unknown
- 2010-02-11 CA CA2752434A patent/CA2752434C/en active Active
- 2010-02-11 HU HUE10703474A patent/HUE031088T2/en unknown
- 2010-02-11 EP EP16187550.5A patent/EP3144000A1/en not_active Withdrawn
- 2010-02-11 UA UAA201110829A patent/UA103915C2/ru unknown
- 2010-02-11 PE PE2011001438A patent/PE20120018A1/es active IP Right Grant
- 2010-02-12 AR ARP100100419A patent/AR075422A1/es not_active Application Discontinuation
- 2010-02-12 TW TW099104827A patent/TWI483943B/zh active
-
2011
- 2011-06-22 IL IL213721A patent/IL213721A0/en unknown
- 2011-07-20 CL CL2011001758A patent/CL2011001758A1/es unknown
- 2011-08-12 TN TN2011000414A patent/TN2011000414A1/fr unknown
- 2011-08-16 CO CO11103911A patent/CO6410287A2/es not_active Application Discontinuation
- 2011-08-16 EC EC2011011276A patent/ECSP11011276A/es unknown
-
2017
- 2017-12-19 US US15/846,897 patent/US20180104249A1/en not_active Abandoned
-
2021
- 2021-11-19 US US17/530,559 patent/US20220331326A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075422A1 (es) | Composicion farmaceutica que comprende linagliptina, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
| AR078517A1 (es) | Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos para su tratamiento y sus usos | |
| Li et al. | Honokiol protects pancreatic β cell against high glucose and intermittent hypoxia-induced injury by activating Nrf2/ARE pathway in vitro and in vivo | |
| Wang et al. | Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress | |
| AU2010360116B2 (en) | Use of AVE0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 | |
| UY29694A1 (es) | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido | |
| Soliman et al. | Sequential therapy with minocycline and candesartan improves long-term recovery after experimental stroke | |
| Mohammed et al. | Review on diabetes, synthetic drugs and glycemic effects of medicinal plants | |
| JP2013529617A5 (es) | ||
| Liang et al. | The neuroprotective and antidiabetic effects of trigonelline: A review of signaling pathways and molecular mechanisms | |
| Bernard et al. | NADPH oxidase inhibition in fibrotic pathologies | |
| CN107441104B (zh) | 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途 | |
| Mohankumar et al. | Insulinotrophic and insulin-like effects of a high molecular weight aqueous extract of Pterocarpus marsupium Roxb. hardwood | |
| WO2024131769A1 (zh) | 一种用于防治糖尿病及其并发症的人参二醇皂苷组合物及其制备方法和应用 | |
| JP2020502140A5 (es) | ||
| Jiang et al. | Catalpol ameliorates doxorubicin‑induced inflammation and oxidative stress in H9C2 cells through PPAR‑γ activation | |
| Zhang et al. | The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlying signaling mechanisms in a rat model of diabetes mellitus | |
| O'Keefe et al. | Sglt inhibitors for improving healthspan and lifespan | |
| Davidson | Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies | |
| Pathak et al. | Therapeutic repurposing of antidiabetic drugs in diabetes-associated comorbidities | |
| US20080118589A1 (en) | Pharmaceutical formulations of rhodiola crenulata and methods of use thereof | |
| BR112012026005A2 (pt) | composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados | |
| Zhang et al. | The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy | |
| TWI526206B (zh) | 用於調節糖尿病之異戊二烯類黃酮化合物 | |
| Ruan et al. | Melatonin decreases GSDME mediated mesothelial cell pyroptosis and prevents peritoneal fibrosis and ultrafiltration failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |